Monika Tedeschi
Urology · Norfolk, VANPI 1407344823
Payments from drug & device makers
Across 82 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$474
- AbbVie$273
- Boston Scientific$176
- Ferring Pharmaceuticals Inc.$160
- Davol Inc.$158
- Bayer$155
- plus $757 from 18 others
What the payments were for
- Food & beverage$2,152100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 23 | $474 |
| AbbVie | 12 | $273 |
| Boston Scientific | 2 | $176 |
| Ferring Pharmaceuticals Inc. | 7 | $160 |
| Davol Inc. | 2 | $158 |
| Bayer | 6 | $155 |
| Myovant Sciences Inc. | 1 | $93 |
| Teleflex LLC | 4 | $78 |
| Progenics Pharmaceuticals, Inc. | 3 | $76 |
| Astellas Pharma US Inc | 3 | $61 |
| Stryker | 1 | $57 |
| Verity Pharmaceuticals Inc. | 3 | $53 |
| Endo Pharmaceuticals Inc. | 2 | $49 |
| 180 Medical, Inc. | 2 | $46 |
| Johnson & Johnson | 2 | $44 |
| Tolmar, Inc. | 1 | $29 |
| Endo USA, Inc. | 1 | $28 |
| Calyxo, Inc. | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Blue Earth Diagnostics | 1 | $24 |
| Halozyme Inc | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| Coloplast | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,152 in reported general payments places this provider in the 45th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 36 | $406 |
| Finasteride | 17 | $306 |
| Cephalexin | 19 | $90 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $56 |
Paid to pharmacies, not to this prescriber.
Other urology in Norfolk
- Robert GivenVirginia Beach$8.7M
- Michael WilliamsVirginia Beach$2.7M
- Michael FabrizioVirginia Beach$1.6M
- Gregg EureVirginia Beach$1.5M
- Nilay GandhiWoodbridge$1.3M
- Jessica DelongVirginia Beach$644K
- Eugene KramolowskyRichmond$594K
- Nicolas OrtizCharlottesville$331K
- Stephen CulpCharlottesville$284K
- Michael FranksRichmond$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.